One year ago, when we were finalizing our outlook for 2020, the world was in the early throes of the COVID-19 pandemic. While we anticipated that 2021 would bring many new challenges, few, if any, of us predicted at the time...more
4/13/2021
/ Business Litigation ,
Coronavirus/COVID-19 ,
Corporate Governance ,
Corporate Sales Transactions ,
Forum Selection ,
Infectious Diseases ,
Material Adverse Effects ,
Publicly-Traded Companies ,
Securities Litigation ,
Securities Regulation ,
Shareholders
Below is our Quarterly Corporate / M&A Decisions Update for decisions in Q4 2020. This update is designed to highlight selected important M&A, corporate, and commercial court decisions on a quarterly basis. Brief summaries of...more
2/19/2021
/ Acquisition Agreements ,
Breach of Duty ,
Contract Terms ,
Coronavirus/COVID-19 ,
Corporate Sales Transactions ,
D&O Insurance ,
Delaware General Corporation Law ,
Fiduciary Duty ,
Generic Drugs ,
Gilead Sciences ,
Infectious Diseases ,
Material Adverse Effects ,
Merger Agreements ,
Section 220 Request ,
Shareholder Litigation
This update is designed to highlight selected important M&A, corporate and commercial court decisions on a quarterly basis. Brief summaries of each decision appear below with links to more robust discussions.
...more
These updates are designed to highlight selected important M&A, corporate and commercial court decisions on a quarterly basis. ...more
This update is designed to highlight selected important M&A, corporate and commercial court decisions on a quarterly basis. The update contains brief summaries of each decision with links to more robust discussions.
...more
This update is designed to highlight selected important M&A, corporate and commercial court decisions on a quarterly basis. The update contains brief summaries of each decision with links to more robust discussions.
...more
We’ve put lawyers from our offices in Spain, France, Germany, the Netherlands, and the U.S. on the spot. Having got them thinking about when they’ve been up against shareholders in M&A litigation, we asked for pointers you...more